Research programme: bromodomain and extraterminal domain protein inhibitors - Jubilant Biosys/Checkpoint Therapeutics/TG Therapeutics

Drug Profile

Research programme: bromodomain and extraterminal domain protein inhibitors - Jubilant Biosys/Checkpoint Therapeutics/TG Therapeutics

Alternative Names: BET inhibitors; BRD4 Inhibitors - Jubilant/Checkpoint; CK-103; TG 1601

Latest Information Update: 24 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jubilant Biosys
  • Developer Checkpoint Therapeutics; Jubilant Biosys; TG Therapeutics Inc
  • Class Antineoplastics; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in cancer presented at the at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 21 Apr 2018 TG Therapeutics plans a clinical trial of TG 1601 for Cancer in the first half of 2018
  • 20 Apr 2018 TG therapeutics plans a clinical trial in Cancer (combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top